Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization

Area of Science:

• Immunology
• Dermatology
• Oncology

Background:

• Percutaneous peptide immunization (PPI) is a novel method for inducing cytotoxic T lymphocyte (CTL) responses.
• It involves delivering peptides through the skin after removing the stratum corneum, a key barrier.
• Epidermal Langerhans cells mature but show reduced dendrites after this disruption.

Purpose of the Study:

• To evaluate the efficacy and safety of PPI in inducing CTL responses.
• To assess the therapeutic potential of PPI in patients with advanced melanoma.

Main Methods:

• Skin barrier disruption followed by peptide delivery.
• Monitoring of immune cell populations (CD8+ T cells, IFN-gamma production) in blood.
• Assessment of tumor response (lesion size, tumor development) in melanoma patients.
• Evaluation of in vitro CTL activity and immune cell infiltration in regressing lesions.

Main Results:

• PPI successfully induced HLA class I-restricted antigenic peptide-specific CTL responses, evidenced by IFN-gamma production.
• In advanced melanoma patients, PPI with melanoma-associated peptides led to reduced lesion size and suppressed tumor development in a majority of cases.
• Therapeutic benefits correlated with the generation of circulating CTLs and infiltration of specific immune cells into regressing tumors.
• PPI demonstrated a favorable safety profile, with no significant local or systemic toxicity or autoimmunity, apart from vitiligo in some melanoma patients.

Conclusions:

• Percutaneous peptide immunization (PPI) is a safe and effective method for generating potent CTL responses.
• PPI represents a promising novel therapeutic strategy for cancer treatment, particularly in advanced melanoma.
• The noninvasive nature and favorable safety profile make PPI a valuable clinical intervention.